Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial

C. Byrd, John; Hillmen, Peter; Ghia, Paolo; P. Kater, Arnon; Chanan-Khan, Asher; R. Furman, Richard; O’Brien, Susan; Nuri Yenerel, Mustafa; Illés, Árpád; E. Kay, Neil; A. García‐Marco, José; R. Mato, Anthony; Pinilla‐Ibarz, Javier; F. Seymour, John; Leprêtre, Stéphane; Stilgenbauer, Stephan; Robak, Tadeusz; Rothbaum, Wayne; Izumi, Raquel; Hamdy, Ahmed; Patel, Priti; Higgins, Kara; Sohoni, Sophia; Jurczak, Wojciech

doi:10.1200/jco.21.01210

Public

Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial

Published in Journal of Clinical Oncology • Jul 26, 2021

Authors:

John C. Byrd

Peter Hillmen

Paolo Ghia

Abstract

PURPOSE Among Bruton's tyrosine kinase inhibitors, acalabrutinib has greater selectivity than ibrutinib, which we hypothesized would improve continuous therapy tolerability. We conducted an open-label, randomized, noninferiority, phase III trial comparing acalabrutinib and ibrutinib in patients with...

Subject

Ibrutinib

Medicine

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!